Spironolactone for PCOS: Dosing, Monitoring, and Contraindications
Spironolactone is an effective off-label treatment for hirsutism in women with PCOS, typically started at 50-100 mg daily, with combination oral contraceptive therapy strongly recommended for contraception and menstrual regulation. 1, 2
Primary Indication and Mechanism
Spironolactone functions as an aldosterone receptor antagonist with potent antiandrogen activity, decreasing testosterone production and competitively blocking androgen receptors in the skin 2. While the FDA has not approved spironolactone for PCOS treatment, ACOG guidelines support combining an antiandrogen (spironolactone) with an ovarian suppression agent (oral contraceptive) as the most effective approach to hirsutism in PCOS 1.
Dosing Strategy
Start with 50-100 mg daily 2, 3. The evidence shows:
- 50 mg daily: Effective for hirsutism with fewer side effects, particularly menstrual irregularities 3
- 100 mg daily: Standard dose with demonstrated efficacy; 66% of women showed marked improvement 2
- Up to 200 mg daily: Can be used but side effects increase substantially in a dose-dependent manner 4, 2
Critical timing consideration: Several months of treatment (typically 3-6 months) are required to reach full effectiveness 4, 3.
Mandatory Contraception Requirement
Spironolactone is Pregnancy Category C and causes feminization of male fetuses in animal studies 4, 2, 5. Therefore:
- Concomitant oral contraceptive use is essential in all women of reproductive potential 2
- This combination also minimizes menstrual irregularities (the most common side effect occurring in 15-30% of patients) 4, 2
- The combination of spironolactone 100 mg with norgestimate-ethinyl estradiol shows superior hirsutism reduction compared to other protocols 6
Monitoring Requirements
Potassium Monitoring
In young, healthy women with PCOS: Potassium monitoring is NOT required 4, 2. This is based on evidence showing only 0.75% of 1,723 potassium measurements exceeded 5.0 mmol/L in women aged 18-45 taking spironolactone 50-200 mg daily 2.
Potassium monitoring IS required for:
- Older patients
- Renal insufficiency (baseline creatinine >2.5 mg/dL) 5
- Cardiovascular disease
- Concomitant use of ACE inhibitors, ARBs, NSAIDs, or digoxin 2, 5
When monitoring is indicated: Check at baseline, within 1 week of initiation or dose titration, and regularly thereafter 5.
Other Monitoring
- Blood pressure measurement before initiating treatment 2
- Counsel patients to avoid high-potassium foods (low-sodium processed foods, coconut water) 2
Expected Outcomes
Based on comparative evidence 3:
- Hirsutism score: Decreased from 12.9 to 8.7 at 6 months with spironolactone 50 mg (superior to metformin)
- Menstrual cyclicity: Improved from 6.6 to 10.2 cycles/year at 6 months
- Testosterone levels: Significant reduction in both groups
- Insulin sensitivity: Improvement observed, though metformin showed greater effect
Common Side Effects (Dose-Dependent)
- Menstrual irregularities: 15-30% (relative risk 4.12 at 200 mg vs lower doses) 4, 2
- Breast tenderness: 3-5% 4
- Diuresis: 29% 2
- Dizziness: 3-4% 4
- Nausea: 2-4% 4
- Headache: 2% 4
Absolute Contraindications
- Pregnancy or inadequate contraception 4, 2
- Baseline serum potassium >5.0 mEq/L 5
- Severe renal impairment (creatinine >2.5 mg/dL) 5
- Severe heart failure 4, 5
- Hyperkalemia risk factors without appropriate monitoring 5
Safety Considerations
The black box warning regarding tumorigenicity is not clinically relevant 4, 2. Multiple large cohort studies with over 30 million person-years of follow-up found no increased cancer risk at clinical doses 4. Animal studies used doses 100-150 times higher than human therapeutic doses 2, 5.
Clinical Pitfalls to Avoid
- Do not use spironolactone without concurrent contraception in women of reproductive potential
- Do not routinely monitor potassium in young, healthy women without risk factors—this leads to unnecessary testing
- Do not expect rapid results—counsel patients that 3-6 months of treatment is needed
- Do not use in men with PCOS features—causes gynecomastia 2
- Do not discontinue oral contraceptives to "see if periods regulate"—this increases pregnancy risk
Comparison with Alternative Treatments
While metformin improves insulin sensitivity and ovulation rates in PCOS 1, spironolactone demonstrates superior efficacy for hirsutism and menstrual cyclicity 3. Recent systematic reviews show no significant difference between spironolactone and metformin for Ferriman-Gallwey scores, but spironolactone remains preferred for hyperandrogenic symptoms 7, 8.
For women not attempting conception: Spironolactone 50-100 mg daily plus oral contraceptive is the evidence-based first-line approach for hirsutism in PCOS 1, 2, 1.